Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 5 institutions in 3 countries.
Fei TangCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.ORCID http://orcid.org/0000-0003-1475-5028
Peng ZhangCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.ORCID http://orcid.org/0000-0002-6218-1885
Peiying YeCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.
Christopher A LazarskiCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.
Qi WuDepartment of Neurology, University of Michigan Medical School, Ann Arbor, United States.
Ingrid L BerginULAM In-Vivo Animal Core, University of Michigan Medical School, Ann Arbor, United States.
Timothy P BenderDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, United States.
Michael N HallBiozentrum, University of Basel, Basel, Switzerland.
Ya CuiKey Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Liguo ZhangKey Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Taijiao JiangKey Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Yang LiuCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.ORCID http://orcid.org/0000-0002-9442-700X
Pan ZhengCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, United States.ORCID http://orcid.org/0000-0003-2598-3544
Children's National · USChinese Academy of Sciences · CNUniversity of Michigan · USUniversity of Basel · CHUniversity of Virginia · US
Funding
Checkpoints of Host Response to Cellular InjuriesR01AI064350 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIU, YANG, ZHENG, PAN · 2006 to 2019
$5.6M
Targeted Elimination of Cancer Stem Cells for AML TherapyR01CA171972 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI LIU, YANG, MALEK, SAMI NIMER · 2013 to 2017
$2.3M
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AMLU01CA183030 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI LIU, YANG, SCHORE, REUVEN J · 2014 to 2017
$2.3M
mTOR, Inflammation and Senescence of Hematopoietic Stem CellsR01AG036690 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHENG, PAN · 2010 to 2014
$1.6M
c-Myb controls survival, proliferation and differentiation during B-lymphopoiesisR01GM100776 · NIGMS · UNIVERSITY OF VIRGINIA · PI BENDER, TIMOTHY P. · 2011 to 2014
Adaptive autoimmunity is restrained by controlling population sizes and pathogenicity of harmful clones, while innate destruction is controlled at effector phase. We report here that deletion of
Indexed as
AutoimmunityCell ProliferationImmunity, InnateAnimalsAntigens, SurfaceGene DeletionImmunophenotypingLymphocyte SubsetsMechanistic Target of Rapamycin Complex 1MiceRegulatory-Associated Protein of mTORAntigens, SurfaceMechanistic Target of Rapamycin Complex 1Regulatory-Associated Protein of mTORRptor protein, mousehemotopoiesisimmune toleranceimmunologyinflammationinnate immunitymousemTORC1TSC-mTOR signaling
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. · full record | OpenQuestion